Table 2 The presence of a marker... | American Society of Hematology

Table 2

The presence of a marker chromosomal abnormality or JAK2V617F status of SP MF-NRCs following the treatment with AZD1480

Patient no.	NRCs assayed
Patient no.	CD34⁺ cells treated with cytokines alone, %		CD34⁺ cells treated with cytokines + AZD1480, %
	JAK2V617F in BM hCD45⁺ cells	JAK2V617F in spleen hCD45⁺ cells	JAK2V617F in BM hCD45⁺ cells	JAK2V617F in spleen hCD45⁺ cells
SP9	0	0	0	0
SP10	88	72	79	65
	BM hCD45⁺ cells with chromosomal abnormality	Spleen hCD45⁺ cells with chromosomal abnormality	BM hCD45⁺ cells with chromosomal abnormality	Spleen hCD45⁺ cells with chromosomal abnormality
SP7	81	96	98	100
SP8	100	100	100	100
SP9	0	0	0	0

Patient no.	NRCs assayed
Patient no.	CD34⁺ cells treated with cytokines alone, %		CD34⁺ cells treated with cytokines + AZD1480, %
	JAK2V617F in BM hCD45⁺ cells	JAK2V617F in spleen hCD45⁺ cells	JAK2V617F in BM hCD45⁺ cells	JAK2V617F in spleen hCD45⁺ cells
SP9	0	0	0	0
SP10	88	72	79	65
	BM hCD45⁺ cells with chromosomal abnormality	Spleen hCD45⁺ cells with chromosomal abnormality	BM hCD45⁺ cells with chromosomal abnormality	Spleen hCD45⁺ cells with chromosomal abnormality
SP7	81	96	98	100
SP8	100	100	100	100
SP9	0	0	0	0